Hong Kong Stock Exchange · Healthcare
Invest in Beijing Luzhu Biotechnology stock from India
Indian and foreign residents can buy Beijing Luzhu Biotechnology (2480) shares directly through Paasa.
By Paasa · Updated
Beijing Luzhu Biotechnology at a glance
- Price
- HK$13.40-HK$0.10 (0.74%)
- Market cap
- HK$2.67B
- Day range
- HK$13.40 – HK$13.40
- P/E
- —
- Dividend yield
- None
- Volume
- 200.00
- 1 month
- -1.47%
- 6 months
- -41.64%
- YTD
- -43.22%
- 1 year
- -45.97%
- 5 years
- —
How to invest in Beijing Luzhu Biotechnology from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to HKD when you buy.
Step 3
Search 2480 and buy
Find Beijing Luzhu Biotechnology by name or by its ticker, 2480, and place your order. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
Why invest in Beijing Luzhu Biotechnology from India
What Beijing Luzhu Biotechnology does
Beijing Luzhu Biotechnology Co., Ltd., a biotechnology company, develops human vaccines and therapeutic biologics to prevent and control infectious diseases, and to treat cancer and autoimmune diseases in Mainland China. The company is developing LZ901, a recombinant herpes zoster vaccine for which a biologics license application (BLA) has been submitted; K3, a recombinant human anti-tumor necrosis factor-alpha monoclonal antibody injection that has completed a Phase 1 clinical trial for the treatment of autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and plaque p… Beijing Luzhu Biotechnology operates in the Biotechnology industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Beijing Luzhu Biotechnology stock from India?
Yes. Indian residents and NRIs can buy Beijing Luzhu Biotechnology (2480) shares directly through Paasa. Beijing Luzhu Biotechnology is listed on the Hong Kong Stock Exchange, in the Biotechnology industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
Do I need to buy a full Beijing Luzhu Biotechnology share?
Usually more than one, and not a fraction: many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. At HK$13.40 a share, size the order by the lot, not by the share.
How are Beijing Luzhu Biotechnology dividends taxed for Indian investors?
Beijing Luzhu Biotechnology trades on the Hong Kong Stock Exchange but is domiciled in China, so any withholding on its dividends follows that country's rules rather than those of Hong Kong. Dividends are taxed at your slab rate in India. Paasa's dividend report shows the gross amount and any tax withheld for each payment.
What tax do I pay in India when I sell Beijing Luzhu Biotechnology shares?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the HKD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.